Effect of hydroxyurea in sickle cell anemia: A clinical trial in children and teenagers with severe sickle cell anemia and sickle cell β- thalassemia

Pediatric Hematology and Oncology

Volumn 16, Issue 3, 1999, Pages 221-232

  Koren, Ariel ^a,b,c,e   Segal Kupershmit, Dora ^d   Zalman, Lucia ^a   Levin, Carina ^a   Hana, Manhal Abu ^a   Palmor, Haya ^a   Luder, Anthony ^d   Attias, Dina ^c  

^a HAEMEK MEDICAL CENTER   (Israel)

^b Baruch Rappaport School of Medicine   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^d Ziv Hospital   (Israel)

^e BNAI ZION MEDICAL CENTER   (Israel)

Author keywords

Children; Hydroxyurea; Sickle cell anemia

Indexed keywords

HYDROXYUREA;

ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HEMOLYSIS; HUMAN; MALE; NEUTROPENIA; SCHOOL CHILD; SICKLE CELL ANEMIA; SPLEEN;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; BETA-THALASSEMIA; BONE MARROW; CHILD; FEMALE; HUMANS; HYDROXYUREA; MALE;

EID: 0032957295     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.1080/088800199277272     Document Type: Article

References (26)

1. Hebbel RP, Yamada O, Moldow CF, Jacob HS, White JG, Eaton JW. Abnormal adherence of sickle erythrocytes to cultured vascular endothelium. J Clin Invest. 1980;65:154-160.
2. Mohandas N, Evans E, Kukan B. Adherence of sickle erythrocytes to vascular endothelial cells: requirement for both cell membrane changes and plasma factors. Blood. 1984;64:282-287.
3. Charache S. Fetal hemoglobin, sickling, and sickle cell disease. Adv Pediatr. 1990;37:1-31.
4. Letvin ML, Linch DC, Beardsley GP, McIntire KW, Nathan DG. Augmentation of fetal-hemoglobin production in anemic monkey by hydroxyurea. N Engl J Med. 1984;310:869-873.
5. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 1995;332:1317-1322.
6. Scott JP, Hillery CA, Brown ER, Misiewicz V, Labotka RJ. Hydroxyurea therapy in children severely affected with sickle cell disease. J Pediatr. 1996;128:820-828.
7. Ferster A, Vermylen C, Crnu G, et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood. 1996;88:1960-1964.
8. Watson J, Stahman AW, Bilello FP. The significance of the paucity of sickle cells in newborn negro infants. Am J Med Sci. 1948;215:419-423.
9. Perrine RP, Pembrey ME, John P, Perrine S, Shoup F. Natural history of sickle cell anemia in Saudi Arabs. Ann Intern Med. 1978;88:1-6.
10. Hurta RA, Wright JA. Amplification of the genes for both components of ribonucleotide reductase in hydroxyurea resistant mammalian cells. Biochem Biophys Res Commun. 1990;167:258-264.
11. Noguchi CT, Schechter AN, Rodgers GP. Sickle cell disease pathophysiology. Bailliere's Clin Haematol. 1993;6:57-91.
12. Adragna NC, Fonseca P, Lauf PK. Hydroxyurea affects cell morphology, cation transport, and red blood cell adhesion in cultured vascular endothelial cells. Blood. 1994;83:553-560.
13. Charache S. Hydroxyurea as treatment for sickle cell anemia. Hematol Oncol Clin North Am. 1991;5:571-583.
14. Marwick C. Trial halted as sickle cell treatment proves itself. JAMA. 1995;273:611.
15. Voscaridou E, Kalotychou V, Loukopoulos D. Clinical and laboratory effects of long-term administration of hydroxyurea to patients with sickle-cell/β-thalassaemia. Br J Haematol. 1995;89:479-484.
16. Claster S, Vichinsky E. First report of reversal of organ dysfunction in sickle cell anemia by the use of hydroxyurea: splenic regeneration. Blood. 1996;88:1951-1953.
17. Ware RE, Steinberg MH, Kinney TR. Hydroxyurea: an alternative to transfusion therapy for stroke in sickle cell anemia. Am J Hematol. 1995;50:140-143.
18. Nand S, Messmore H, Fisher SG, Bid ML, Schulz W, Fisher RI. Leukemic transformation in polycythemia vera: analysis of risk factors. Am J Hematol. 1990;34:32-36.
19. Fruchtman SM, Kaplan ME, Peterson P, Mack K, Berk PD. Acute leukemia (AL), hydroxyurea (HU), and polycythemia vera (PV): an analysis of risk from the Polycythemia Vera Study Group. Blood. 1994;84(Suppl 1):518a, abstract.
20. Ferrari D, Ticozzelli G, De Vizzi M, Corigliano P, De Vizzi G. Essential thrombocythemia and acute leukemia. Hematologica. 1993;78:401-402.
21. Furgerson JL, Vukelja SB, Baker WJ, O'Rourke TJ. Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea. Am J Hematol. 1996;51:137-140.
22. Triadou P, Maier-Redelsperger M, Krishnamoorty R. Fetal haemoglobin variations following hydroxyurea treatment in patients with cyanotic congenital heart disease. Nouv Rev Fr Hematol. 1994;36:367-372.
23. Charache S, Barton FB, Moore RD, et al. Hydroxyurea and sickle cell anemia: clinical utility of a myelosupressive "switching" agent. Medicine. 1996;75:300-326.
24. Donehower RC. An overview of the clinical experience with hydroxyurea. Semin Oncol. 1992;19 (Suppl 9):11-19.
25. Adams-Graves P, Heltsley C, Deitcher S. Hydroxyurea in sickle cell disease. N Engl J Med. 1996;334: 333-334.
26. Jackson N, Shukri A, Ali K. Hydroxyurea treatment for chronic myeloid leukemia during pregnancy. Br J Haematol. 1993;85:203-204.